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Introduction
The burden of breast cancer remains huge worldwide. Incidence rates are partly explained by the distribution of risk factors associated with a greater lifetime cumulative exposure to estrogens; notably, age, early menarche, late menopause, nulliparity, late first full-term pregnancy, lack of breast feeding, and hormone replacement therapy [1] [2] [3] [4] . Family history also plays a role. However, these factors alone do not explain the magnitude of changes in incidence rates. Considerable attention has been paid to the role of exposure to endocrine-disrupting chemicals (EDCs); nevertheless, studies that analyzed the association between the body burden of individual EDCs and cancer risk have yielded inconsistent results [5] [6] [7] [8] [9] [10] [11] .
Research on these issues faces difficult challenges, which may explain some lack of consistency in results. The association between body burden of xenoestrogens and breast cancer is likely to vary among population or ethnic groups or among subgroups exposed to different mixtures of environmental chemicals [12, 13] , limiting the replication of results. Studies that do not measure exposures in periods of life critical for cancer development may also underestimate risks [9, 11, 14, 15] . Moreover, individual xenoestrogens can interact with each other and with other environmental, dietary, lifestyle, and reproductive factors, which are not systematically measured across studies [13, 16] . Crucially, a hypothetical association between xenoestrogens and breast cancer risk cannot be tested solely through measures of the concentrations of individual compounds; account must be taken of possible synergetic, additive, or antagonistic interactions among them [10, [17] [18] [19] .
Humans are exposed to multi-component chemical mixtures present in the environment [12, 13] . Over the past decades, a wide variety of synthetic chemicals have been demonstrated to have estrogenic effects [9, 17] . Xenoestrogen assessment based exclusively on chemical analysis appears to be unrealistic given the multitude of residues to be measured and the structural diversity of these compounds [20] . It has therefore been proposed to evaluate the potential contribution of the total effective estrogenic burden (TEXB) in biological samples, using a specific bioassay for estrogenicity, as a reliable marker of the combined effect of mixtures of xenoestrogens in the organism. TEXB comprises two fractions; TEXB-alpha, which indicates the estrogenicity of the lipophilic fraction (including most persistent pollutants), and TEXBbeta, which is largely influenced by endogenous estrogens (but also containing more polar xenoestrogens) [17] . Using this approach, two breast cancer case-control studies have provided evidence of a significant relationship between cancer risk and the combined effect of environmental estrogens in human adipose tissue [21] , and the estrogenic potential of EDC mixtures present in blood samples [22] . TEXB-alpha at the time of surgery was associated with environmental, dietary, lifestyle, genetic, and reproductive factors [23, 24] .
All previous studies assessed TEXB in a single sample taken at breast surgery [21, 22, 24] , and no data are available on TEXB during the follow-up of breast cancer patients to evaluate the influence of treatment (chemotherapy and/or radiotherapy) or tumor progression. It is critical to know whether cancer treatment modifies xenoestrogen content in the organism, whether TEXB is influenced by this modification, and how TEXB evolves during the clinical course. These issues are also relevant for methodological research on biomarkers [25] .
Our objective was to assess changes in TEXB levels in newly-diagnosed breast cancer patients between the time of surgery and at four time post-surgical points during follow-up (<6 months, 6-12 months, 12-18 months, and >18 months), and to analyze the potential influence of socio-demographic, reproductive, tumor, and treatment characteristics on TEXB values.
Material and Methods

Study design and population
The available study population was all women with newly diagnosed breast cancer scheduled for surgery at San Cecilio University Hospital, Granada (Southern Spain) during [2002] [2003] . Exclusion criteria were the presence of gynecological or endocrinal disease, history of cancer, and refusal to sign informed consent. After application of these criteria, a final study sample of 56 women was obtained. All women were Caucasian, resided in Granada Province, and diagnosed with infiltrating ductal carcinoma. The study had a prospective longitudinal design and participants were followed up until June 2004. Breast adipose samples were obtained during the surgery and abdominal adipose samples (fat pad aspiration) during the follow up. Surgical treatments were: tumorectomy and axillary lymphadenectomy (12%), quandrantectomy and homolateral lymphadenectomy (40%), and the Madden technique (48%), a modified radical mastectomy [26] . In our study most patients (83.6%) were treated post-surgery with antineoplastic drugs, with only a small variation in the schedule and type. Most of them received Adriamycin and Cyclophosphamide, for four cycles, followed by either no further therapy or four cycles of Taxol. Three out of four (75%) also received radiotherapy. Patients completed antineoplastic treatment during the first year post-surgery. None of the subjects received neoadjuvant (before surgery) chemotherapy treatment, neither hormonal treatment during the follow up period.
Structured face-to-face interviews were conducted at the hospital by a trained interviewer to gather data on socio-demographic characteristics, reproductive history and fertility, menopausal status, use of exogenous hormones, diet, tobacco and alcohol consumption, and family history of breast cancer.
Clinical-pathological information was also collected from medical records, including details on diagnostic procedures and laboratory results. Patients were classified according to pathology reports based on histological study and tumor size, lymph node involvement, and metastasis (TNM). Tumors were also classified as estrogen receptor (ER) and/or progesterone receptor (PR) positive depending on the immunostaining (intensity of reactivity and number of cells observed under light microscopy, and following a semi-quantitative scale (considering 0 as negative, and 1 +, 2 + and 3 + categories as light, moderate, and intense positive, respectively). Hospital discharge data were also recorded. The study was approved by the ethics committee of the hospital.
Sample collection and follow-up
Fifty five patients agreed to participate in the study. All women had at least one adequate adipose tissue sample, interview reports, and estrogenicity bioassay results. Only 52 breast adipose samples were obtained at the time of surgery. Adequate abdominal adipose samples after surgery were available for: 37 women, during first 6 months (median 95 days), 25 women between 6-12 months (median 192 days), 29 women at 12-18 months (median 371 days), and 26 women at >18 months (median 542 days). Women were followed for a median time of 16.8 months after surgery. Of the 52 patients with sample at the time of surgery, 44 had at least an additional sample during the follow-up, 33 had two more, and 21 had three samples. For n=14, adipose tissue were available at surgery, <6 months, 6-12 months or 12-18 months, and >18 months. At each follow-up session, height and weight were measured, and body mass index (BMI-Kg/m 2 ) calculated. 
Chromatographic conditions and quality control analysis
TEXB assessment
After HPLC fractionation, duplicated of each fraction were combined, dry and resuspended in 2.5 ml of experimental steroid-free medium (phenol red-free medium supplemented with charcoal-dextran fetal bovine serum), and tested for estrogenic activity with the E-Screen bioassay [28] . Each fraction was Lipid content was quantified gravimetrically [27] .
The limit of detection (LOD) for TEXB-alpha and TEXB-beta was 0.1 Eeq pM/mL, which corresponded to the minimum concentration of estradiol needed to produce a significantly different proliferative effect from that observed in steroid-free control cells (negative control). When a sample had a concentration below the detection threshold, it was assigned the mid-value of this limit.
For quality control, 10 adipose samples were analyzed in triplicate through independent extraction, HPLC fractionation, and E-Screen bioassay. The inter-assay coefficients of variation for TEXB-alpha and TEXB-beta were 17.1% and 12.2%, respectively. In addition, researchers responsible for the extraction, fractionation, and cell culture (E-Screen) analysis were blinded to the characteristics of the study population
Statistical analysis
Univariate statistics were computed as customary [29, 30] . The Kruskal-Wallis test and Mann-Whitney We did not consider performing multivariate analysis of repeated measures for several reasons. First, the limited number of repeated adipose tissue samples from the same women, both at surgery and at the follow-up measurements. Second, the limited available data for some variables in the different follow-up points, such as for example BMI. Third, for many women the time intervals of different follow up points overlapped. And finally, the very low TEXB values at surgery compared to the "second follow-up measurement" allow interpret results using linear regression models in an approximate way to those obtained in the analysis for repeated measures, without losing participants. The statistical significance level was set at 0.05, and all tests were two-tailed. SPSS version 18 (SPSS, Armonk, NY, USA, 2009) was used for analyses. Table 1S ) shows TEXB-alpha and -beta levels at surgery and during follow-up. Median TEXB-alpha and -beta values significantly increased during follow-up (p < 0.001, Kruskal Wallis test), were maximal at 6-12 months, and then decreased lightly with time. Statistical significant differences (p < 0.001, Mann-Whitney's U test) were also found between TEXB-alpha and beta median values estimated at surgery and those at 6-12 months, between surgery and 6-18 months, and between surgery and >18 months. Interestingly, TEXB-alpha or -beta levels in breast adipose tissue collected at surgery (2.5 and 16.1 pM Eeq/g lipid, for TEXB-alpha and -beta, respectively) and the earliest abdominal fat samples (first follow-up measurement) (<6 months, 5.3 and 17.0 pM Eeq/g lipid, for TEXB-alpha and -beta, respectively) were similar and not statistically different. These samples were obtained before the onset of chemotherapy and/or radiotherapy treatment. Maximal significant differences (p < 0.001, MannWhitney's U test) were found between median values at 6-12 months (174 and 252 pM Eeq/g lipid for TEXB-alpha and -beta, respectively) and levels at surgery (Table 1S ). In addition, a slight and statistically non-significant decrease in mean and median TEXB-alpha and -beta values was observed between the top values (6-12 months) and final follow-up measurements (12-18 months, and > 18 months).
Results
When we analyzed individual data for the patients (n=14) in whom TEXB was obtained at four time points (surgery, <6 months, 6-12 months or 12-18 months, and >18 months), we again found a significant increase in median TEXB values over the follow-up period (p < 0.001, Friedman test).
The greatest increase in TEXB values was observed for those patients (n=32) with TEXB-alpha and -beta values at surgery (median 1.7 and 13.8 pM Eeq/g lipid for TEXB-alpha and -beta) and at 6-18 months-"second follow-up measurement" (median 169 and 320 pM Eeq/g lipid for TEXB-alpha and -beta, respectively) ( Table 2) . Among those women a significant correlation was also observed between TEXBalpha and -beta values; and it became weaker over time: the coefficient ρ was 0.619 (p <0.01) at surgery and 0.372 (p ≤0.030) at the "second follow-up measurement". The median crude increase in TEXB-alpha values (surgery vs. second follow-up measurement) was 9 pM Eeq/g lipid in non-chemotherapy treated patients and 165 pM Eeq/g lipid in chemotherapy patients, being statistically significant only in the latter (p < 0.001).
The potential influence of socio-demographic, reproductive, tumor, and treatment characteristics on the TEXB-alpha values at the "second follow-up measurement" were assessed by GLM models. First, main effects of all predictors were independently explored. Second, the model was adjusted by age as a potential confounder (Table 3) , TEXB-alpha (pM Eeq/ml) levels were significantly associated with high- however, bioavailability was not assessed in our study. Further research is needed to understand the role of xenoestrogens in the progression of breast and other cancers.
A potential study limitation is first that adipose tissue was obtained from mammary gland at the time of surgery and from parietal adipose tissue during follow-up, because these tissues may differ in fat composition and/or rates of accumulation of lipophilic xenoestrogens. Nevertheless, we found no differences in TEXB values between mammary tissue at surgery and parietal fat obtained at the first follow up (<6 months), confirming a previous report [17, 21] that TEXB values of mammary and parietal adipose tissue are equivalent when lipid-adjusted ( Figure 1 , Table S1 ). In addition, according to Petreas et al., [50] measurements in breast and abdominal adipose tissues were correlated and that concentrations of environmental pollutants in one tissue could be derived from measurements in the other tissue. Moreover, the distribution of xenoestrogens in fatty tissues appears to be more dependent on the nature rather than site of tissue, and differences in xenoestrogen accumulation between organs largely depend on the lipid content of tissues [50, 51] . In this regard, breast, liver, omental fat, and subcutaneous fat are known to contain similar concentrations of chlorinated pesticides and their metabolites and of PCBs [52] .
Therefore, regardless of the specific xenoestrogens responsible for the TEXB-alpha, it is plausible that they are similarly distributed in mammary fat and subcutaneous adipose tissue. Secondly, sample size in the present study is somewhat limited. Nevertheless, it was sufficient to perform this exploratory study and to yield statistically significant associations. In addition, it should be borne in mind that studies with repeated measures from abdominal fat are extremely uncommon in this and other research areas.
Our goal was also to respond to the often stated but seldom practiced methodological requirement to collect multiple samples of biomarkers over time from individual study participants [25] ; the results illustrate how challenging this requirement remains. It is necessary to emphasize the exploratory character of the present study, which gave interesting and potentially relevant results (a profound variation of TEXB values during the follow-up of patients) and set the basis for future confirmatory studies.
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